Kenvue Inc. $KVUE Position Trimmed by Keybank National Association OH

Keybank National Association OH cut its stake in shares of Kenvue Inc. (NYSE:KVUE) by 35.1% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,055,555 shares of the company’s stock after selling 571,857 shares during the period. Keybank National Association OH owned approximately 0.05% of Kenvue worth $18,198,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Norges Bank acquired a new position in Kenvue in the 4th quarter worth approximately $756,862,000. Independent Franchise Partners LLP raised its stake in Kenvue by 56.3% during the 4th quarter. Independent Franchise Partners LLP now owns 48,146,476 shares of the company’s stock valued at $830,527,000 after purchasing an additional 17,343,785 shares during the period. Sculptor Capital LP raised its stake in Kenvue by 1,023.5% during the 4th quarter. Sculptor Capital LP now owns 12,886,328 shares of the company’s stock valued at $222,289,000 after purchasing an additional 11,739,328 shares during the period. Capitolis Liquid Global Markets LLC lifted its holdings in shares of Kenvue by 1,116.8% in the fourth quarter. Capitolis Liquid Global Markets LLC now owns 10,950,999 shares of the company’s stock valued at $188,905,000 after purchasing an additional 10,050,999 shares in the last quarter. Finally, Cibc World Markets Corp purchased a new stake in shares of Kenvue in the fourth quarter valued at $162,193,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of NYSE KVUE opened at $19.81 on Friday. The business’s 50-day moving average price is $17.86 and its two-hundred day moving average price is $17.71. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70. Kenvue Inc. has a one year low of $14.02 and a one year high of $22.87. The company has a market capitalization of $38.03 billion, a P/E ratio of 23.30, a price-to-earnings-growth ratio of 1.50 and a beta of 0.47.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The company had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. During the same period in the prior year, the firm posted $0.24 EPS. The business’s revenue was up 4.5% compared to the same quarter last year. Analysts anticipate that Kenvue Inc. will post 1.16 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were issued a $0.2075 dividend. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a yield of 4.2%. Kenvue’s dividend payout ratio is currently 97.65%.

Wall Street Analyst Weigh In

KVUE has been the subject of several recent analyst reports. Argus raised Kenvue to a “hold” rating in a research report on Friday, March 6th. Citigroup dropped their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 15th. Zacks Research raised Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. Barclays decreased their price objective on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 14th. Finally, Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have issued a Hold rating to the company. Based on data from MarketBeat, Kenvue presently has a consensus rating of “Hold” and an average target price of $19.33.

Insiders Place Their Bets

In related news, General Counsel Matthew Orlando sold 38,491 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 1.59% of the company’s stock.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.